Genetic Susceptibility to Factor VIII Inhibitors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1187 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-05-24

Study Completion Date

2016-04-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This international study will identify genetic factors that may influence the development of inhibitory antibodies in patients with hemophilia A after treatment with factor VIII. Bleeding episodes in patients with inhibitors are often more difficult to treat. Previous research indicates that genetic factors play a role in the development of inhibitors. A better understanding of the influence of genes in this treatment complication may be helpful in predicting, treating or preventing inhibitors.

People in families in which one or more members have severe factor VIII deficiency and one or more have a history of an inhibitor may be eligible for this study. Participants fill out a form with questions about the person's relationship to other family members taking part in the study. Those with hemophilia provide a brief medical history, including hemophilia-related information, inhibitor history and the presence of other conditions such as hepatitis C and HIV. All participants have a blood sample taken for laboratory and research tests.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385

Hemophilia A

WITHDRAWN PHASE4

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

NCT03405337

Hemophilia A

COMPLETED

Cooperative Study of Factor VIII Inhibitors

NCT00000582

Blood Coagulation Disorders Hematologic Diseases Hemophilia A +1 more

COMPLETED PHASE3

Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

NCT00178607

Hemophilia A

COMPLETED

Inhibitor Development in Patients With Hemophilia A Undergoing Surgery

NCT01571934

Hemophilia A

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In collaboration with investigators of the Hemophilia Inhibitor Genetic Study (HIGS) multicenter study and the University of Lund, University Hospital, Malmo, Sweden, we propose to assess the role of genetic variants in the process of developing inhibitors to Factor VIII in persons with hemophilia. The discovery of genetic associations offers the potential to direct clinical management in order to prevent inhibitor development and improve clinical care in patients with inhibitors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DNA and relevant clinical data from properly consented hemophiliac subjects and family members (maximum estimated = 3500) will be provided to the LGD for genotyping and analysis.